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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S321transcripted into cDNA. The mmu-miR-381-3p mimic/inhibitor were
transfected into cells with lipofectamine 2000. The miR-381-3p in
mouse embryo and degraded cartilage was stained with insitu
hybridization method.
Results: The miR-381 expression was elevated in chondrogenic ATDC5.
The in situ hybridization assay identiﬁed the presence of miR-381 in
degraded cartilage of osteoarthritis patients and in enchondral bone
formating claws of mouse embryo.
The miR-381 obviously suppressed the collagen 2 expression and
enhanced mmp13 expression.
Conclusions: The miR-381 may participate in chondrogenesis and
cartilage degradation by alleviating collagen 2 expression and
enhancing mmp13 expression.Nutraceuticals/ Dietary Supplements and OA
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SHELLS FROM ROSE-HIP (ROSA CANINA) DO NOT REDUCE SYMPTOM
SCORES OR IMPROVE ANTI-INFLAMMATORY PROPERTY IN PATIENTS
WITH OSTEOARTHRITIS – A DOUBLE-BLIND, PLACEBO-CONTROLLED,
RANDOMIZED STUDY
K. Winther. Frederiksberg and Bispebjerg Hosp., Univ. of Copenhagen,
Copenhagen NV, Denmark
Purpose: Placebo controlled studies on a standardised rose-hip powder,
Hyben-Vital, based on daily intake of 2.5 g seeds and 2.5 g shells,
indicate alleviation of symptoms from osteoarthritis. The same powder
also shows anti-inﬂammatory properties, by lowering C-reactive pro-
tein (CRP) and erythrocyte sedimentation rate. On the latest OARSI
meeting, data from a partly blinded, exploratory study, on rose-hip
powder, based exclusively on shells, was presented. The study, which
did not include placebo or measurements of inﬂammatory markers,
suggested that the shell powder (2.25 g daily) could have equal, orperhaps stronger effect, than the double dose of said shell powder (4.5 g
daily), or even the original Hyben-Vital powder (5 g daily) containing
50% shells and 50% seeds. An inverse dose-response curve, where less
powder gives higher response, was introduced in the study. The
inclusion of a placebo arm would have made the study even stronger.
The present study, therefore, aims to test whether this low-dose shell
powder shows any impact on symptoms of OA and/or reduction in CRP,
when tested against placebo treatment.
Methods: Ninety-four patients, a sub fraction from a study on the
occurrence of common cold during the winter season (ClinicalTrials.gov
Identiﬁer NCT 01459952), all diagnosed with OA according to the cri-
teria of the American College of Rheumatology, participated in the
present study. Forty-seven patients received 90% rosehip shells and 10%
rose hip seeds in total (2.20 gram daily) and the remaining forty-seven
patients received placebo of similar taste and colour. All patients were
followed for 6 months. Pain and stiffness was estimated on a numerical
scale from 0-10 (more symptom - higher score) and patient’s global
assessment of disease severity (PGAD)was estimated on a 100mm scale
(WOMAC). Quality of life was estimated using SF-12, and CRP by normal
laboratory routine. The Wilcoxon tested within groups and the Man-
Whitney was used when comparing groups. A p-value less than 0.050
was regarded as statistically signiﬁcant. All data given is on the inten-
tion to treat basis. To further test if an impact from active treatment, if
present, was based on treatment it self or was possibly random - a dose
dependency tests - wasmade on both groups by testing for a correlation
between patient weight and symptom score.
Results: Pain declined as a result of active treatment from 4.72 þ/- 2.41
to 3.44 þ/- 2.19 (p<0.050). Placebo resulted in similar results: 4.91 þ/-
3.07 declined to 3.99 þ/-2.74, p<0.086. Man-Whitney p value <0.880.
Stiffness likewise declined in both groups. Active treatment: 3.57 þ/-
2.38 declined to 2.95 þ/- 1.88 (p<0.236) and placebo: 4.50 þ/- 2.93
declined to 3.80 þ/- 2.85, (p<0.033). Man-Whitney p value: 0.274. No
signiﬁcant change was observed in PGAD: active treatment 31.0 þ/-21
changing to 33.0 þ/-20.0 (p<0.527) and placebo 42.0 þ/-27 unchanged
42.0 þ/-24.0 (p<0.541). Mann-Whitney p-value 0.520. Quality of life
(SF-12 physical and SF-12 psychological) did not show any changes
(data not given). CRP remained unchanged during both treatments,
Mann-Whitney p-value: 0.347. There was no correlation between
patient weight and the change in symptom scores in either of the two
groups at any time point of the study (data not given). This demon-
strates a lack of effect of shell powder treatment. The lighter patient at
60 kg had the same lack of effect as had the heavier patient at 110 kg.
Conclusions: In regards to impact on symptom scores of OA, quality of
life and reduction in CRP, low-dose rose-hip powder based mainly on
shells, is comparable to placebo. The effect in symptom scores of OA,
quality of life and reduction in CRP seen in previous studies on stand-
ardised rose-hip powder from Rosa canina may be highly dependent on
the higher content of seeds.
560
LOW-DOSE SEED AND SHELL POWDER FROM ROSE-HIP (ROSA
CANINA) CAN ALEVIATE SYMPTOMS OF OSTEOARTHRITIS AND
REDUCE C-REACTIVE PROTEIN IN PATIENTS SUFFERING FROM
OSTEOARTHRITIS
K. Winther. Frederiksberg and Bispebjerg Hosp., Univ. of Copenhagen,
Copenhagen NV, Denmark
Purpose: A meta-analysis has shown that a standardised rose-hip
powder, Hyben-Vital containing seeds and shells from Rosa canina,
reduces symptoms of osteoarthritis (OA), when used in the dose of 5 g
daily. The same remedy can also reduce markers of inﬂammation. The
aim of the present study was to test if the aforementioned rose-hip
powder, when given as a booster of 5 grams daily for 3 weeks, then
followed by 2.5 g for the following 9 weeks, would alleviate symptoms
of osteoarthritis and reduce C-reactive protein (CRP) in patients suf-
fering from OA of the hip or knee.
Methods: The study (ClinicalTrials.gov Identiﬁer NCT01459939) inclu-
ded 120 patients who were allocated randomly to either active treat-
ment: 5 grams daily for the ﬁrst 3 weeks followed by 2.5 gram daily for
the following 9 weeks, or placebo in a similar dose and of similar colour,
taste and smell. All the patients were diagnosed with OA according to
the criteria of the American College of Rheumatology. The WOMAC
questionnaire was used throughout. The primary effect variables were
pain and activity of daily living (ADL). A Secondary effect variable was
stiffness. CRP was estimated using normal laboratory routine. The
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comparing groups. Signiﬁcance level was a p-value of <0.05. All data
given are on the basis of the intention to treat (ITT). To test for a possible
dose-dependency the bodyweight of each patient was plotted against
the different symptom scores, and a correlation test was made on each
of the two groups at the initial level and after 6 and 12 weeks of
treatment.
Results: The two groups were comparable at the initial level regarding
age, sex, bodyweight, consumption of rescue medication and the
severity of OA. Twelveweeks of active treatment resulted in a reduction
inWOMAC pain from 17.79 þ/- 8.80 to 16.57þ/-9.88, p<0.14, whilst the
placebo group showed a decline in pain score from 17.96þ/-7.08 to
14.41 þ/-7.60, p<0.001. Comparing groups yielded a Man-Whitney p-
value of 0.058. No correlation was present between weight and pain
score in either of the two groups on the day of inclusion. After both 6
and 12 weeks of active treatment, there was a signiﬁcant negative
correlation between weight and pain score (p<0.021 and p<0.022,
respectively). The lower the weight the more pronounced the reduction
in pain. No correlation was observed at any time point during placebo.
The ADL score declined from 60.59 þ/-31.33 to 53.91 þ/- 30.59 after 12
weeks of active treatment (p<0.016). Placebo resulted in a decline from
55.71 þ/-25.19 to 43.90 (p<0.001). Comparing groups yielded a Man-
Whitney p-value of 0.098. There was no correlation between weight
and ADL score in either of the two groups on the day of inclusion. Six
and 12 weeks of active treatment, however, resulted in a negative
correlation between weight and ADL score (p<0.019 and p<0.009
respectively). To summarize, the less the weight of the patient the
better the impact from treatment. In the placebo group there was no
signiﬁcant correlation betweenweight and ADL score at any time point.
Similar results for active treatment and placebo were obtained when
testing the secondary effect variable. CRP signiﬁcantly declined as a
result of active treatment. Man-Whitney p-value 0.042.
Conclusions: The present data suggest that patients with osteoarthritis
of the knee or hip can beneﬁt from treatment with the present rose-hip
powder, when given a booster of 5 grams daily for 3 weeks, followed by
2.5 g for the following 9 weeks, with the effect becoming statistically
signiﬁcant in the group of patients of lower weight than 84 kg. This low-
dose also signiﬁcantly reduces CRP.
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EGCG SLOWS POST-TRAUMATIC OA PROGRESSION: IN VIVO
EVIDENCE AND A NOVEL MECHANISM UNDERLYING THE
DOWNREGULATION OF ADAMTS5
D.J. Leong y, Z. He y, D.M. Hirsh y, S.J. Kim y, K.E. Sperling y,
R.J. Majeska z, M.B. Schafﬂer z, J.A. Hardin y, N.J. Cobelli y, H.B. Sun y.
yAlbert Einstein Coll. of Med., Bronx, NY, USA; z The City Coll. of NY, New
York, NY, USA
Purpose: There is currently no cure for osteoarthritis (OA), or therapies
which slow or arrest OA progression. Given the nature of OA, decades-
long treatment will likely be required to arrest or slow its progression.
Consequently, there is an urgent need for OA disease-modifying
therapies which in the best case scenario also improve symptoms, and
are safe for clinical use over long periods of time. Nutraceuticals are
derived from food, are generally safe, and provide not only medical or
health beneﬁts, but also exert potential disease- and symptom-mod-
iﬁcation effects in OA. EGCG (epigallocatechin 3-gallate) is a major
bioactive polyphenol present in green tea. Although it remains to be
conﬁrmed by in vivo and clinical studies, recent studies suggest that
EGCG may exert chondroprotective effects in vitro. In this study, we
addressed the question whether EGCG could prevent or slow pro-
gression of post-traumatic OA in vivo. To further dissect the mechanism
underlying EGCG chondroprotection, we: 1) examined the effect of
EGCG in vitro cultured C28/I2 chondrocytes; 2) analyzed the effect of
EGCG on NF-kB subunit p65 and its potential co-factor acetylated H3
(Ac-H3) on ADAMTS5 transactivation using a chromatin immunopre-
cipitation (ChIP) assay.
Methods: EGCG (50 mg/kg) was administered 5 days/week by intra-
peritoneal injection in C57BL/6 mice (male, 5-6 months) subject to
destabilization of the medial meniscus (DMM), starting the same day of
DMM surgery for four weeks (n¼6/group). Limbs from DMMmice were
then sacriﬁced and OA severity was evaluated by Safranin O staining
and OARSI score. Immunohistochemical analysis was performed to
detect cleaved aggrecan (NITEGE), denatured type II collagen (Col2 3/
4M), and expression of MMP-13 and ADAMTS5. C28/I2 chondrocyteswere cultured to semi-conﬂuence and were treated with EGCG for 6
hours in the presence and absence of IL-1b and were harvested for RT-
qPCR. For ChIP assay, cell lysates were immunopreciptated (IP) with
antibodies speciﬁc to p65, acetylated H3, or control IgG. Amounts of
speciﬁc DNA fragments were quantiﬁed by real-time PCR using primers
speciﬁc for p65 binding sites in the ADAMTS5 promoter region and
normalized against the genomic DNA preparation from the same cells
(input).
Results: In vivo: Four weeks after EGCG treatment, the cartilage in the
DMM limb in the EGCG-treated mice exhibited signiﬁcantly less
Safranin O loss and cartilage ﬁbrillation, and lower OARSI score com-
pared to vehicle-treated controls (Fig 1A, B). Administration of EGCG
protected cartilage integrity by reducing degradation of aggrecan and
type II collagen, and suppressed expression of MMP-13 and ADAMTS5
(Fig 1C). In vitro: EGCG suppresses expression of ADAMTS5 in chon-
drocytes in the presence of IL-1b (Fig 2A). ChIP assay revealed EGCG
reduces p65 binding and histone H3 on the p65 binding sites of the
ADAMTS5 promoter as shown by reduced PCR-ampliﬁed DNA products
(Fig 2B). This data suggests EGCG suppresses ADAMTS5 expression by,
at least in part, interrupting p65 binding to the promoter of ADAMTS5
through a mechanism that involves Ac-H3.
Conclusions: We demonstrated efﬁcacy of EGCG in slowing OA pro-
gression by preserving cartilage integrity and suppressing key cartilage
degradative enzymes. Our ﬁndings provide a rational basis for
advancing EGCG-based treatments toward future clinical trials and
treatment. Furthermore, the molecular mechanisms uncovered could
provide novel molecular targets for the treatment of OA.
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SULFORAPHANE REPRESSES MATRIX-DEGRADING PROTEASES AND
PROTECTS CARTILAGE FROM DESTRUCTION IN VITRO AND IN VIVO
R.K. Davidson y, O. Jupp y, R. de Ferrars y, C.D. Kay y, K.L. Culley y,
R. Norton y, C. Driscoll z, T.L. Vincent z, S.T. Donell y, Y. Bao y, I.M. Clark y.
yUniv. of East Anglia, Norwich, United kingdom; zUniv. of Oxford, Oxford,
United Kingdom
Purpose: Nutrition impacts directly on ageing and obesity, both of
which are major risk factors for osteoarthritis. Sulforaphane (SFN) is an
isothiocyanate derived from brassicas, particularly broccoli, and has
been reported to regulate signalling pathways relevant to chronic dis-
eases. Our study investigated whether sulforaphane can abrogate car-
tilage destruction in laboratory models of osteoarthritis and examined
mechanism of action in chondrocytes.
Methods: The impact of SFN treatment on gene expression, signalling
through transcription factors nuclear factor (erythroid-derived 2)-like 2
(Nrf2) and nuclear factor kappaB (NFkB), and histone acetylation were
examined in chondrocytes. The intracellular concentrations of SFN and
SFN metabolites were quantiﬁed in chondrocytes and used to inform
transcription factor binding assays. The bovine nasal cartilage explant
model (BNC) and destabilisation of medial meniscus (DMM) murine
model of osteoarthritis were used to study chondroprotection by SFN.
Results: SFN inhibited cytokine-induced metalloproteinase expression
in primary human articular chondrocytes (HACs) and in ﬁbroblast-like
synovial cells (FLS). SFN can act independently of the Nrf2 transcription
factor and histone deacetylase activity in HACs, but does mediate pro-
longed activation of Jun kinase (JNK) and p38 MAP kinase. SFN
